Sexual Dysfunctions, Psychological Clinical Trial
Official title:
Randomized, Double-blind, Two-arms Study With Parallel Groups to Determine the Effect of a Phosphodiesterase Inhibitor for 14 Weeks of Treatment Versus Placebo in Women With FSIAD.
This clinical trial is a prospective, randomized, double-blind Phase III study with two arms
to determine the efficacy and safety of the use of an IPDE in women with FSIAD.
Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will
enter the study and receive active product or placebo for 14 weeks.
Patients will be assigned to each treatment group in a randomized and parallel manner. In
addition, all volunteers participating in the study will receive medical advice during the
study.
The study will have a duration of minimum of 18 weeks and will consist of 3 periods.
This clinical trial is a prospective, randomized, double-blind Phase III study with two arms
to determine the efficacy and safety of the use of an IPDE in women with FSIAD.
Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will
enter the study and receive active product or placebo for 14 weeks.
Patients will be assigned to each treatment group in a randomized and parallel manner. In
addition, all volunteers participating in the study will receive medical advice during the
study.
The study will have a duration of minimum of 18 weeks and will consist of 3 periods
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00996372 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
|
Phase 3 | |
| Completed |
NCT00996164 -
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
| Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
| Completed |
NCT01188720 -
Sexual Health on Antidepressants Through Physical Exercise
|
N/A | |
| Completed |
NCT00175539 -
Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties
|
N/A | |
| Completed |
NCT04792177 -
Internet-based Emotion Regulation Intervention for Sexual Health
|
N/A | |
| Completed |
NCT02381912 -
Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
|
N/A | |
| Completed |
NCT03241524 -
Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women
|
N/A | |
| Completed |
NCT00491829 -
Flibanserin Versus Placebo in Premenopausal Women With HSDD
|
Phase 3 | |
| Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
| Recruiting |
NCT05489133 -
Early Psychological Intervention After Rape
|
N/A | |
| Completed |
NCT03775239 -
Mindfulness as Treatment of Sexological Problems
|
N/A | |
| Completed |
NCT01654458 -
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
|
N/A | |
| Completed |
NCT01188603 -
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 1 | |
| Completed |
NCT01771237 -
HIV Prevention Among Vulnerable Male Youth
|
N/A | |
| Completed |
NCT00360243 -
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
|
Phase 3 | |
| Completed |
NCT00360555 -
A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
| Completed |
NCT00360529 -
24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
|
Phase 3 | |
| Recruiting |
NCT05456919 -
Quality of Sexual Function in BRCA Mutated Women
|
||
| Terminated |
NCT01057901 -
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
|
Phase 3 |